Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.

about

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.

Item

http://www.wikidata.org/entity/Q47131401

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@en

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@nl

type

Item

label

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@en

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@nl

prefLabel

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@en

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@nl

P1476

Treatment Persistence and Heal ...... Changing Biologics in the USA.

@en

P2093

Andreas Kuznik

http://www.w3.org/2001/XMLSchema#string

Chieh-I Chen

http://www.w3.org/2001/XMLSchema#string

Clare Proudfoot

http://www.w3.org/2001/XMLSchema#string

Shraddha Shinde

http://www.w3.org/2001/XMLSchema#string

Wenhui Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

P2888

s12325-017-0617-5

P304

2422-2435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-017-0617-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

B Chastek

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29039054

http://www.w3.org/2001/XMLSchema#string

P932

5702369

http://www.w3.org/2001/XMLSchema#string